
Libtayo shows increased survival benefit in high-risk skin cancer after nearly 4 years follow-up
Regeneron's Libtayo (cemiplimab) demonstrates a growing overall survival benefit for high-risk cutaneous squamous cell carcinoma (CSCC) patients after nearly four years of follow-up in the Phase 3 C-POST trial. The data reveal a 37% reduction in deat...





